The EVERY Company

The EVERY Company has done what most precision-fermentation startups only promise: put a fermentation-made animal protein on national retail shelves and shown the demand curve bending sharply upward. It brews recombinant egg proteins — including egg-white ovalbumin — without chickens, and its OvoPro egg-white protein reached US retail through Walmart and Target, moving the company, in one investor's phrase, "from promise to proof." The 2026 signal is the loudest one in this batch: annual orders for OvoPro grew 550% in the first four months of 2026 versus all of 2025, driven by B2B retail placement plus e-commerce and foodservice adoption. The macro backdrop is a genuine tailwind — recurring avian-flu outbreaks send conventional egg prices spiking and supply crashing, and a drop-in, allergen-free, chicken-free egg protein is exactly the hedge food manufacturers want against that volatility. Founded in 2014 (as Clara Foods) with roughly $294M raised across a decade including a $55M Series D led by McWin Capital Partners in late 2025, EVERY is one of the most mature and best-capitalized names in fermentation-made ingredients. It sells B2B into the binding, foaming, gelling and fortification functions egg performs everywhere, a vast and unglamorous market where a functional, price-competitive replacement compounds quietly.

Precision fermentation's core problem is cost: brewing egg protein in bioreactors is structurally more expensive than a hen laying an egg, and outside the acute windows when avian flu spikes commodity egg prices, EVERY's proteins struggle to compete on a cents-per-gram basis with an ingredient that is one of the cheapest functional proteins on earth. A 550% order jump off a small 2025 base is a percentage that flatters a still-modest absolute volume; the durable question is whether adoption holds when egg prices normalize and the emergency substitution rationale fades. The company has been at this since 2014 and raised nearly $300M to reach retail — a long, capital-hungry road for a business whose latest round was a $55M Series D "first close," a structure that can signal a harder fundraising environment than the headline implies. The broader alt-protein and fermentation capital markets are severely depressed, and EVERY competes with other animal-free egg and protein players plus incumbent egg processors and ingredient giants who can bundle and undercut. Precision fermentation for commodity food ingredients has repeatedly foundered on the gap between technical success and cost parity; EVERY's traction is real, but the model still rests on either sustained scale-driven cost reduction or a persistent egg-supply crisis — neither guaranteed.